{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:40:29Z","timestamp":1790023229883,"version":"4.0.1"},"reference-count":29,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Asthma and bronchiectasis appear to be two related diseases and in their complex inflammatory interaction, the cysteinyl leukotriene\/cysteinyl leukotriene receptor 1 (cysLT\/cysLTR1) axis appears to play an important role given its involvement also in the neutrophilic pathway. To our knowledge, few studies have been conducted so far to evaluate the role of the leukotriene cysLT\/cysLTr1 axis in the management of clinical and inflammatory outcomes within a population of patients with severe asthma and bronchiectasis. The aim of our study was to verify in this population the effect of leukotriene receptor antagonist (LTRA) therapy in clinical and inflammatory control before and after 6 months of introduction of biologic therapy. Methods: We retrospectively enrolled, from eight different severe asthma centers\u2019 outpatients, 36 atopic patients with the simultaneous presence of non-cystic fibrosis (non-CF) and non-allergic bronchopulmonary aspergillosis (non-ABPA) bronchiectasis and severe asthma. The first biological injection was performed at baseline (T0 time). Patients who were already taking LTRA therapy at time T0 were recorded, and no new prescriptions were made. We observed our population over a 6-month period (T1 time). At the baseline we collected the following data: baseline characteristics, clinical history, high resolution computed tomography and bronchiectasis-related parameters and skin prick test. At both times T0 and T1 we collected the following data: asthma control test (ACT), asthma control questionnaire (ACQ), immunoglobulin E (IgE) level, blood count, fractional exhaled nitric oxide 50 (FeNO 50) and flow-volume spirometry. The study was retrospectively registered. Results: Our population had a mean age of 59.08 \u00b1 11.09 and 50% were female. At T1, patients on LTRA therapy had a significantly lower FeNO value (33.03 \u00b1 23.61 vs. 88.92 \u00b1 77.96; p = 0.012). We assessed that the value of \u0394FeNO (FeNO 50 T1 \u2212 FeNO 50 T0) and the number of unplanned specialist visits allowed a discrimination of 66.7% in the presence of LTRA therapy. We also verified how low FeNO values at time T1 were statistically significant predictors of LTRA therapy (ODD = 9.96 (0.94\u20130.99); p = 0.032). Conclusion: The presence of LTRA in therapy in a population of severe asthmatics with coexisting non-ASBPA bronchiectasis and non-cystic fibrosis, acting simultaneously on the T helper type 2 (TH2) pathway and probably on the neutrophilic component of bronchiectasis, would allow a further amplification of the beneficial effects of biological therapy, leading to a reduction in the number of unplanned visits to specialists.<\/jats:p>","DOI":"10.3390\/jcm11164702","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T21:15:05Z","timestamp":1660252505000},"page":"4702","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study"],"prefix":"10.3390","volume":"11","author":[{"given":"Vitaliano","family":"Quaranta","sequence":"first","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Respiratory Disease, University \u201cAldo Moro\u201d of Bari, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Dragonieri","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Respiratory Disease, University \u201cAldo Moro\u201d of Bari, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzio","family":"Crimi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Specialistic Medicine, Section of Respiratory Diseases, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9088-5214","authenticated-orcid":false,"given":"Claudia","family":"Crimi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Specialistic Medicine, Section of Respiratory Diseases, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3462-8253","authenticated-orcid":false,"given":"Pierachille","family":"Santus","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biomedical Sciences, Division of Respiratory Diseases, Universit\u00e0 degli Studi di Milano, \u201cL. Sacco\u201d University Hospital, ASST Fatebenefratelli-Sacco, 20157 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3950-5789","authenticated-orcid":false,"given":"Francesco","family":"Menzella","sequence":"additional","affiliation":[{"name":"Pulmonology Unit, S. Valentino Hospital, 31044 Montebelluna City, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4236-7367","authenticated-orcid":false,"given":"Corrado","family":"Pelaia","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Respiratory Disease, University \u2018\u2018Magna Gr\u00e6cia\u2019\u2019 of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2667-077X","authenticated-orcid":false,"given":"Giulia","family":"Scioscia","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University Hospital Policlinico Riuniti of Foggia, 71122 Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7631-029X","authenticated-orcid":false,"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[{"name":"UOSD DH Gastroenterology Polyclinic Foundation A. Gemelli IRCCS, Department of Medical and Surgical Sciences, Cattolica University del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-3703","authenticated-orcid":false,"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[{"name":"Respiratory Diseases and Lung Transplant Unit, Department of Medical and Surgical Sciences and Neurosciences, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0774-3942","authenticated-orcid":false,"given":"Konstantinos","family":"Kostikas","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Department, University of Ioannina School of Medicine, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8806-2561","authenticated-orcid":false,"given":"Christos","family":"Kyriakopoulos","sequence":"additional","affiliation":[{"name":"Respiratory Medicine Department, University of Ioannina School of Medicine, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6400-6573","authenticated-orcid":false,"given":"Nicola","family":"Scichilone","sequence":"additional","affiliation":[{"name":"Promise Department, University of Palermo, 90133 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Carpagnano","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Respiratory Disease, University \u201cAldo Moro\u201d of Bari, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1800328","DOI":"10.1183\/13993003.00328-2018","article-title":"The overlap between bronchiectasis and chronic airway diseases: State of the art and future directions","volume":"52","author":"Polverino","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1590\/S1807-59322009000800010","article-title":"Comorbidities in severe asthma: Frequency of rhinitis, nasal polyposis, gastroesophageal reflux disease, vocal cord dysfunction and bronchiectasis","volume":"64","author":"Bisaccioni","year":"2009","journal-title":"Clinics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1398-9995.2010.02542.x","article-title":"Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma","volume":"66","author":"Menzies","year":"2011","journal-title":"Allergy"},{"key":"ref_4","unstructured":"Global Iniative for Asthma (GINA) 2022 (2022, July 13). Global Strategy for Asthma Management and Prevention, 2022. Update 2022. Available online: www.ginasthma.org."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_6","first-page":"1","article-title":"British Thoracic Society Guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"992","DOI":"10.21037\/jtd.2016.03.72","article-title":"Importance of fractional exhaled nitricvoxide in diagnosis of bronchiectasis accompanied with bronchial asthma","volume":"8","author":"Chen","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/JAA.S196200","article-title":"Foschino Barbaro MP. Severe uncontrolled asthma with bronchiectasis: A pilot study of an emerging phenotype that responds to mepolizumab","volume":"12","author":"Carpagnano","year":"2019","journal-title":"J. Asthma Allergy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1164\/ajrccm.151.6.7767536","article-title":"Elevated levels of exhaled nitric oxide in bronchiectasis","volume":"151","author":"Kharitonov","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_10","first-page":"608930","article-title":"Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function","volume":"2014","author":"Theron","year":"2014","journal-title":"Rev. J. Immunol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The Bronchiectasis Severity Index. An international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1398-9995.2011.02728.x","article-title":"Practical guide to skin prick tests in allergy to aeroallergens","volume":"67","author":"Bousquet","year":"2012","journal-title":"Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry, ATS\/ERS Task Force. Practice Guideline","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Practice Guideline","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"American Thoracic Society\/European Respiratory Society (2005). ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am. J. Respir. Crit. Care Med., 171, 912\u2013930.","DOI":"10.1164\/rccm.200406-710ST"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4104\/pcrj.2009.00010","article-title":"The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: Analysis of a multinational cross-sectional survey","volume":"18","author":"Thomas","year":"2009","journal-title":"Prim. Care Respir. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur. Respir. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1183\/09031936.00026313","article-title":"Multidimensional approach to BQNFQ the FACED score","volume":"43","author":"Relat","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/17476348.2019.1670640","article-title":"Asthma pharmacotherapy: An update on leukotriene treatments","volume":"13","author":"Trinh","year":"2019","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/thorax.57.7.586","article-title":"Nitric oxide in chronic airway inflammation in children: Diagnostic use and pathophysiological significance","volume":"57","author":"Narang","year":"2002","journal-title":"Thorax"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4046\/trd.2013.74.1.7","article-title":"Measurement of fractional exhaled nitric oxide in stable bronchiectasis","volume":"74","author":"Cho","year":"2013","journal-title":"Tuberc. Respir. Dis."},{"key":"ref_23","first-page":"CD002174","article-title":"Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis","volume":"2","author":"Corless","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.5414\/CP202446","article-title":"Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab","volume":"53","author":"Pouliquen","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/ACI.0000000000000251","article-title":"Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: Evidence and unmet needs","volume":"16","author":"Varricchi","year":"2016","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106491","DOI":"10.1016\/j.rmed.2021.106491","article-title":"Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study","volume":"185","author":"Crimi","year":"2021","journal-title":"Respir. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.rmed.2019.02.003","article-title":"Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma","volume":"150","author":"Katsaounou","year":"2019","journal-title":"Respir. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.anai.2020.11.014","article-title":"Efficacy of type 2-targeted biologics in patients with asthma and bronchiectasis","volume":"126","author":"Kudlaty","year":"2021","journal-title":"Allergy Asthma. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/16\/4702\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:07:25Z","timestamp":1760141245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/16\/4702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":29,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["jcm11164702"],"URL":"https:\/\/doi.org\/10.3390\/jcm11164702","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]}}}